Hints and tips:
Related Special Reports
...CureVac and GSK have yet to start clinical trials but Haas said just because the Covid vaccine makers are out in front now, it does not mean they will have the first approved products for flu....
...Rino Rappuoli, head of vaccines research and development at GSK, said the mRNA technology was a “strategic priority”....
...In 2020, it made an operating loss of €109.8m, which it attributed to increased spending on research....
...“We’re the 1.5, last of the first generation,” said Greg Glenn, head of research and development at the biotech....
...Abbott’s product has a sensitivity of 97.1 per cent, and specificity of 98.5 per cent, according to a clinical study it commissioned....
...Lilly will be responsible for identifying targets, clinical development and commercialisation....
...CureVac has an early clinical trial of an RNA vaccine against rabies and another for prostate cancer. Moderna’s clinical trial programme includes two RNA vaccines against flu and one against Zika....
...Mandy Rutter, head clinical psychologist at Validium, an occupational health consultancy, counts airlines among her clients....
...The deal highlights the growing role of China as a market for western drug companies and, increasingly, as a location for manufacturing and international product research and development....
International Edition